BIIB Insider Trading
BIOGEN INC. | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at BIOGEN INC. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 04:16 | 2026-02-12 | Murphy Nicole | Officer - Head of Pharm Ops and Tech | BUY | $195.04 | 3 | $585 | 19,611 | +0.0% |
| 2026-02-11 01:05 | 2026-02-09 | Singhal Priya | Officer - Head of Development | OPT+S | $199.83 | 2,660 | $531,548 | 8,043 | 0.0% |
| 2026-02-04 01:17 | 2026-02-02 | Singhal Priya | Officer - Head of Development | OPT+S | $179.30 | 748 | $134,116 | 6,271 | 0.0% |
| 2025-09-03 00:56 | 2025-09-02 | Singhal Priya | Officer - Head of Development | OPT+S | $133.55 | 517 | $69,045 | 5,772 | 0.0% |
| 2025-07-17 00:55 | 2025-07-08 | Izzar Rachid | Officer - Head of Global Product Strat. | SELL | $135.00 | 2,223 | $300,105 | 6,330 | -26.0% |
| 2025-05-20 23:05 | 2025-05-19 | Singhal Priya | Officer - Head of Development | SELL | $126.25 | 3,806 | $480,508 | 5,427 | -41.2% |
| 2025-05-05 23:17 | 2025-05-02 | DORSA CAROLINE | Director | BUY | $122.72 | 1,235 | $151,559 | 27,842 | +4.6% |
| 2025-03-10 23:09 | 2025-03-07 | SHERWIN STEPHEN A | Director | SELL | $150.02 | 8,760 | $1,314,142 | 11,318 | -43.6% |
| 2024-12-10 00:57 | 2024-12-09 | Singhal Priya | Officer - Head of Development | OPT+S | $157.21 | 110 | $17,293 | 5,426 | 0.0% |
| 2024-09-05 13:00 | 2024-09-03 | Singhal Priya | Officer - Head of Development | OPT+S | $204.22 | 431 | $88,019 | 5,316 | 0.0% |
| 2024-04-04 03:24 | 2024-04-02 | Singhal Priya | Officer - Head of Development | SELL | $213.09 | 93 | $19,817 | 4,886 | -1.9% |
| 2024-02-27 03:54 | 2024-02-22 | Singhal Priya | Officer - Head of Development | SELL | $221.23 | 262 | $57,962 | 4,886 | -5.1% |
| 2024-02-22 05:27 | 2024-02-16 | Singhal Priya | Officer - Head of Development | OPT+S | $221.49 | 108 | $23,921 | 5,148 | 0.0% |
| 2024-02-21 05:13 | 2024-02-15 | Rowinsky Eric K | Director | BUY | $222.54 | 455 | $101,256 | 20,629 | +2.3% |
| 2024-02-14 02:06 | 2024-02-12 | Singhal Priya | Officer - Head of Development | OPT+S | $239.45 | 419 | $100,330 | 4,516 | 0.0% |
| 2024-02-06 02:38 | 2024-02-02 | Singhal Priya | Officer - Head of Development | OPT+S | $245.93 | 634 | $155,920 | 4,097 | 0.0% |
| 2023-12-13 01:06 | 2023-12-11 | Singhal Priya | Officer - Head of Development | OPT+S | $248.00 | 110 | $27,280 | 3,464 | 0.0% |
| 2023-09-07 01:06 | 2023-09-05 | Singhal Priya | Officer - Head of Development | OPT+S | $269.43 | 431 | $116,124 | 3,354 | 0.0% |
| 2023-07-06 00:33 | 2023-07-03 | Singhal Priya | Officer - Head of Development | OPT+S | $282.87 | 81 | $22,912 | 2,924 | 0.0% |
| 2023-05-03 03:05 | 2023-04-28 | Gregory Ginger | Officer - EVP, Human Resources | SELL | $300.00 | 2,681 | $804,300 | 8,483 | -24.0% |
| 2023-04-07 01:37 | 2023-04-04 | Singhal Priya | Officer - Head of Development | SELL | $277.11 | 91 | $25,217 | 2,843 | -3.1% |
| 2023-03-31 01:31 | 2023-03-28 | Singhal Priya | Officer - Head of Development | SELL | $270.06 | 568 | $153,394 | 2,842 | -16.7% |
| 2022-12-13 04:00 | 2022-11-14 | Gregory Ginger | Officer - EVP, Human Resources | SELL | $300.11 | 5,610 | $1,683,617 | 5,711 | -49.6% |
| 2022-10-29 02:19 | 2022-10-27 | ALEXANDER SUSAN H | Officer - EVP Chief Legal Off & Corp Sec | SELL | $280.70 | 5,532 | $1,552,832 | 39,396 | -12.3% |
| 2021-06-10 02:04 | 2021-06-07 | Guindo Chirfi | Officer - Head of Glob Prod Strat & Com | SELL | $440.00 | 3,087 | $1,358,280 | 2,919 | -51.4% |
| 2021-06-10 02:05 | 2021-06-07 | Sandrock Alfred | Officer - Head of Research & Development | SELL | $440.00 | 7,672 | $3,375,680 | 10,169 | -43.0% |
| 2021-06-08 02:02 | 2021-06-04 | Posner Brian S | Director | SELL | $274.17 | 360 | $98,701 | 7,400 | -4.6% |
| 2021-02-11 00:31 | 2021-02-09 | Mantas Jesus B | Director | BUY | $267.00 | 898 | $239,766 | 2,943 | +43.9% |
| 2020-12-02 00:57 | 2020-11-30 | Vounatsos Michel | Director, Officer - Chief Executive Officer | BUY | $241.31 | 3,100 | $748,047 | 34,810 | +9.8% |
| 2020-11-07 05:39 | 2020-11-04 | Sandrock Alfred | Officer - EVP, Research & Development | SELL | $350.00 | 1,500 | $525,000 | 13,066 | -10.3% |
| 2020-03-13 01:56 | 2020-03-11 | SHERWIN STEPHEN A | Director | OPT+S | $295.22 | 2,434 | $718,574 | 15,438 | 0.0% |
| 2019-12-04 01:58 | 2019-12-02 | Posner Brian S | Director | SELL | $292.35 | 1,055 | $308,429 | 6,995 | -13.1% |
| 2019-05-02 23:30 | 2019-05-01 | Vounatsos Michel | Director, Officer - Chief Executive Officer | BUY | $231.48 | 4,351 | $1,007,169 | 21,007 | +26.1% |
| 2019-05-03 00:06 | 2019-04-30 | DENNER ALEXANDER J | Director | BUY | $229.94 | 118,342 | $27,211,820 | 643,000 | +22.6% |
| 2019-03-19 23:08 | 2019-03-18 | PANGIA ROBERT W | Director | OPT+S | $328.55 | 6,114 | $2,008,755 | 18,587 | 0.0% |
| 2019-02-02 00:19 | 2019-01-30 | DENNER ALEXANDER J | Director | BUY | $327.59 | 62,800 | $20,572,407 | 524,658 | +13.6% |
| 2018-09-27 23:16 | 2018-09-26 | Ehlers Michael D | Officer - EVP, Research and Development | SELL | $350.00 | 1,000 | $350,000 | 4,281 | -18.9% |
| 2018-04-27 14:48 | 2018-04-25 | DENNER ALEXANDER J | Director | BUY | $269.91 | 48,000 | $12,955,680 | 461,858 | +11.6% |
| 2018-03-01 01:39 | 2018-02-27 | Sandrock Alfred | Officer - EVP, Chief Medical Officer | SELL | $290.83 | 259 | $75,325 | 6,553 | -3.8% |
| 2018-02-28 02:25 | 2018-02-23 | Sandrock Alfred | Officer - EVP, Chief Medical Officer | OPT+S | $293.44 | 908 | $266,444 | 6,553 | 0.0% |
| 2018-02-22 00:10 | 2018-02-20 | Sandrock Alfred | Officer - EVP, Chief Medical Officer | SELL | $292.00 | 743 | $216,956 | 6,553 | -10.2% |
| 2018-02-21 04:09 | 2018-02-15 | Sandrock Alfred | Officer - EVP, Chief Medical Officer | SELL | $298.85 | 1,294 | $386,712 | 7,296 | -15.1% |
| 2018-01-11 01:28 | 2018-01-09 | PANGIA ROBERT W | Director | OPT+S | $329.65 | 5,832 | $1,922,519 | 17,707 | 0.0% |
| 2018-01-03 00:21 | 2017-12-29 | Vounatsos Michel | Director, Officer - Chief Executive Officer | BUY | $320.55 | 780 | $250,029 | 4,879 | +19.0% |
| 2017-11-30 15:30 | 2017-11-28 | DENNER ALEXANDER J | Director | BUY | $317.36 | 30,000 | $9,520,800 | 413,858 | +7.8% |
| 2017-07-26 23:22 | 2017-07-25 | ALEXANDER SUSAN H | Officer - EVP Chief Legal Corp Svc & Sec | SELL | $290.01 | 4,974 | $1,442,510 | 22,258 | -18.3% |
| 2017-07-21 00:00 | 2017-07-19 | ALEXANDER SUSAN H | Officer - EVP Chief Legal Corp Svc & Sec | SELL | $285.00 | 7,758 | $2,211,030 | 27,232 | -22.2% |
| 2017-06-12 23:29 | 2017-06-09 | Posner Brian S | Director | SELL | $256.31 | 1,084 | $277,840 | 6,330 | -14.6% |
| 2017-05-02 23:18 | 2017-05-01 | Vounatsos Michel | Director, Officer - Chief Executive Officer | BUY | $271.35 | 1,402 | $380,433 | 2,927 | +91.9% |
| 2017-05-02 00:47 | 2017-04-27 | DENNER ALEXANDER J | Director | BUY | $278.50 | 73,858 | $20,569,475 | 383,858 | +23.8% |
How to Interpret $BIIB Trades
Not every insider transaction in BIOGEN INC. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $BIIB shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for BIIB
Insider activity data for BIOGEN INC. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $BIIB, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.